



IBA Provides Update on its Proton Therapy Business at Capital Markets Day Today

Louvain-la-Neuve, Belgium, October 16, 2012 - **IBA (Ion Beam Applications S.A.)**, the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, is hosting a Capital Markets Day today for analysts and investors at the Company's headquarters in Louvain-la-Neuve, Belgium from 12.00 CET.

Olivier Legrain, Chief Executive Officer and **Jean-Marc Bothy**, Chief Financial Officer will present an overview of IBA's strategy, vision and financials and introduce guest speaker, **Professor Pierre Scalliet**, Head of Radiation Oncology at Saint Luc Hospital, Brussels. Professor Scalliet will give an overview of the proton therapy market, current dynamics and outlook. In addition, **Frederic Genin**, IBA's Executive VP Product Development, will provide an update on IBA's advances in proton therapy technology and the Company's latest proton therapy innovation projects, including Proteus[®]One, its single-room, compact proton therapy solution. No new material information will be presented.

Presentations will be available to download from the Investor Relations section of the Company's website shortly after the session at <http://group.iba-worldwide.com/investor-relations>. A webcast of the event will not be available.

Notes for Editors

About IBA

IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics of cancer. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.



IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at: www.iba-worldwide.com For more information, please contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

For international media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com